These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 28027327)

  • 1. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
    Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
    PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
    Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival Outcomes by
    Meric-Bernstam F; Zheng X; Shariati M; Damodaran S; Wathoo C; Brusco L; Demirhan ME; Tapia C; Eterovic AK; Basho RK; Ueno NT; Janku F; Sahin A; Rodon J; Broaddus R; Kim TB; Mendelsohn J; Mills Shaw KR; Tripathy D; Mills GB; Chen K
    JCO Precis Oncol; 2018; 2018():. PubMed ID: 30035249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic characterization of metastatic breast cancers.
    Bertucci F; Ng CKY; Patsouris A; Droin N; Piscuoglio S; Carbuccia N; Soria JC; Dien AT; Adnani Y; Kamal M; Garnier S; Meurice G; Jimenez M; Dogan S; Verret B; Chaffanet M; Bachelot T; Campone M; Lefeuvre C; Bonnefoi H; Dalenc F; Jacquet A; De Filippo MR; Babbar N; Birnbaum D; Filleron T; Le Tourneau C; André F
    Nature; 2019 May; 569(7757):560-564. PubMed ID: 31118521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy.
    Kim S; Shin D; Min A; Kim M; Na D; Lee HB; Ryu HS; Yang Y; Woo GU; Lee KH; Lee DW; Kim TY; Lee C; Im SA; Kim JI
    J Transl Med; 2021 Jan; 19(1):7. PubMed ID: 33407601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
    Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
    Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
    Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.
    Tang Y; Li J; Liu B; Ran J; Hu ZY; Ouyang Q
    Front Endocrinol (Lausanne); 2022; 13():1075830. PubMed ID: 36518248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts.
    Zhang G; Wang Y; Chen B; Guo L; Cao L; Ren C; Wen L; Li K; Jia M; Li C; Mok H; Chen X; Wei G; Lin J; Zhang Z; Hou T; Han-Zhang H; Liu C; Liu H; Liu J; Balch CM; Meric-Bernstam F; Liao N
    Ann Transl Med; 2019 Apr; 7(8):179. PubMed ID: 31168460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study.
    Callens C; Driouch K; Boulai A; Tariq Z; Comte A; Berger F; Belin L; Bièche I; Servois V; Legoix P; Bernard V; Baulande S; Chemlali W; Bidard FC; Fourchotte V; Salomon AV; Brain E; Lidereau R; Bachelot T; Saghatchian M; Campone M; Giacchetti S; Zafrani BS; Cottu P
    Genome Med; 2021 Mar; 13(1):44. PubMed ID: 33722295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The somatic mutation profile of estrogen receptor-positive HER2-negative metastatic breast cancer in Brazilian patients.
    Reinert T; do Rego FO; Silva MCE; Rodrigues AM; Koyama FC; Gonçalves AC; Pauletto MM; de Carvalho Oliveira LJ; de Resende CAA; Landeiro LCG; Barrios CH; Mano MS; Dienstmann R
    Front Oncol; 2024; 14():1372947. PubMed ID: 38952553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole exome sequencing of rare aggressive breast cancer histologies.
    Dieci MV; Smutná V; Scott V; Yin G; Xu R; Vielh P; Mathieu MC; Vicier C; Laporte M; Drusch F; Guarneri V; Conte P; Delaloge S; Lacroix L; Fromigué O; André F; Lefebvre C
    Breast Cancer Res Treat; 2016 Feb; 156(1):21-32. PubMed ID: 26907767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).
    Liang X; Briaux A; Becette V; Benoist C; Boulai A; Chemlali W; Schnitzler A; Baulande S; Rivera S; Mouret-Reynier MA; Bouvet LV; De La Motte Rouge T; Lemonnier J; Lerebours F; Callens C
    J Hematol Oncol; 2018 Oct; 11(1):124. PubMed ID: 30305115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis.
    Rong G; Yi Z; Ma F; Guan Y; Xu Y; Li L; Xu B
    Ann Transl Med; 2021 Feb; 9(3):220. PubMed ID: 33708847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
    Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q
    EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors.
    Sablin MP; Gestraud P; Jonas SF; Lamy C; Lacroix-Triki M; Bachelot T; Filleron T; Lacroix L; Tran-Dien A; Jézéquel P; Mauduit M; Barros Monteiro J; Jimenez M; Michiels S; Attignon V; Soubeyran I; Driouch K; Servant N; Le Tourneau C; Kamal M; André F; Bièche I
    Br J Cancer; 2024 Oct; 131(6):1060-1067. PubMed ID: 39090361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project.
    Hattori M; Serelli-Lee V; Naito Y; Yamanaka T; Yasojima H; Nakamura R; Fujisawa T; Imai M; Nakamura Y; Bando H; Kawaguchi T; Yoshino T; Iwata H
    JCO Precis Oncol; 2024 Apr; 8():e2300647. PubMed ID: 38635933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
    Ferrando L; Vingiani A; Garuti A; Vernieri C; Belfiore A; Agnelli L; Dagrada G; Ivanoiu D; Bonizzi G; Munzone E; Lippolis L; Dameri M; Ravera F; Colleoni M; Viale G; Magnani L; Ballestrero A; Zoppoli G; Pruneri G
    PLoS Genet; 2023 Jan; 19(1):e1010563. PubMed ID: 36595552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.
    Venetis K; Pepe F; Pescia C; Cursano G; Criscitiello C; Frascarelli C; Mane E; Russo G; Taurelli Salimbeni B; Troncone G; Guerini Rocco E; Curigliano G; Fusco N; Malapelle U
    Cancer Treat Rev; 2023 Dec; 121():102642. PubMed ID: 37864956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.